Pharma — India Patent Cases
730 decisions indexed
Page 15 of 25 · 730 total
Boehringer Ingelheim International GmbH v.The Controller Of Patents & Anr.
Boehringer Ingelheim appealed the Controller's rejection of a divisional patent application related to DPP-IV inhibitors. The core dispute centered on whether the parent application contained a 'plurality of inventions' sufficient to support the new product claims sought in the divisional filing. The Delhi High Court ultimately rejected the appeal, holding that since the original application only contained method or use claims and not distinct product claims, the subsequent introduction of such products was considered disclaimed. Consequently, the divisional application could not proceed.
Astrazeneca Ab v.MSN Laboratories Limited
Astrazeneca filed a suit seeking permanent injunction and damages for infringing Indian Patent IN 297581 related to cancer treatment. The dispute centered on whether a Public Notice issued by the Department of Pharmaceuticals constituted Government Authorization allowing generic manufacturing. The Court clarified that the notice was merely for collating local manufacturer details, not an authorization to infringe.
Novo Nordisk A S v.Union Of India
Novo Nordisk challenged an order by the Deputy Controller of Patents, arguing that the decision did not address the substantive grounds raised in its representation regarding a pending post-grant opposition. The case involves Patent IN257402, which relates to pharmaceutical preparations. Despite years of delays and procedural complexities in the Opposition Board proceedings, the High Court intervened to ensure that the Deputy Controller would consider all arguments presented by the patentee before rendering a final decision.
Novartis Ag v.MSN Laboratories Pvt Ltd
The petitioner filed an application alleging that the defendant violated a prior injunction by offering to supply Eltrombopag Olamine to the Government. The court examined whether this offer, made under Section 100 of the Patents Act, 1970, constituted contempt.
Sanjeev Khandelwal v.Ganesh Medicals
The plaintiff filed a suit alleging infringement of his patents against three defendants. Subsequently, the parties executed a Deed of Compromise dated 22.11.2010. The court disposed of the suit in terms of this compromise, decreeing it against the third defendant and dismissing it against the first and second defendants.
Sanjeev Khandelwal v.Ganesh Medicals
The plaintiff filed a suit alleging infringement of his patent (No. 197822) against three defendants. Subsequently, the parties executed a Deed of Compromise dated 22.11.2010. The court disposed of the suit based on this compromise.
XXX v.Union Of India
The petitioner, suffering from HER2-Negative Metastatic Breast Cancer, sought an interim direction compelling the 3rd respondent (DPIIT) to consider their representation regarding the high cost of Ribociclib. The petitioner argued that since Ribociclib enjoys patent monopoly and is not manufactured in India, compulsory licensing under Section 92 of the Patents Act, 1970, was necessary for affordability.
Sun Pharmaceutical Industries Ltd v.Union Of India & Ors.
The petitions were filed seeking directions to expedite the hearing and adjudication of a post-grant opposition against Patent No. IN 257402, which was facing significant delays by the Respondents (Controller/UOI). The Petitioner also challenged the validity of the Opposition Board's constitution and recommendation.
Chugai Seiyaku Kabushiki Kaisha & Anr. v.Natco Pharma Limited
Plaintiffs (Chugai Seiyaku Kabushiki Kaisha & Anr.) filed a suit seeking permanent injunction against Natco Pharma Limited for infringing Indian Patent No. 294424, which covers the tetracyclic compound Alectinib (Alecensa®). The dispute centered on the Defendant's alleged export and potential commercial launch of generic Alectinib products. The matter was amicably resolved.
Sun Pharmaceutical Industries Ltd v.Union of India
The petitioner filed writ petitions seeking directions to the respondents (Controller/UOI) to expedite the hearing and adjudication of a post-grant opposition against Patent No. IN 257402. The petitioner also challenged the validity of the Opposition Board's recommendation, alleging procedural flaws. The Court directed the Competent Authority to decide the pending representation and scheduled the patent proceedings.
Boehringer Ingelheim Pharma GmbH & Co. KG v.MSN Laboratories Private Limited
The applicants (Boehringer Ingelheim Pharma) filed applications seeking interim directions to restrain the respondents (MSN Laboratories and others) from infringing their patent rights over the medicinal product, Linagliptin. The court found that the defendants had not laid a credible challenge to the validity of the patent and tilted the balance of convenience in favor of the plaintiffs.
Boehringer Ingelheim Pharma GmbH & Co. KG v.MSN Laboratories Private Limited
The plaintiffs, Boehringer Ingelheim Pharma, filed applications seeking interim directions against respondents (including MSN Laboratories and others) for infringing their patent rights related to the medicinal product Linagliptin. The court found that the defendants had not presented a credible challenge to the patent's validity and tilted the balance of convenience in favor of the plaintiffs.
Boehringer Ingelheim Pharma GmbH & Co. KG v.MSN Laboratories Private Limited
The plaintiffs, Boehringer Ingelheim Pharma, filed applications seeking interim directions to restrain respondents from infringing their patent rights related to Linagliptin. The court found that the defendants had not presented a credible challenge to the patent's validity and tilted the balance of convenience in favor of the plaintiffs.
Boehringer Ingelheim Pharma GmbH & Co. KG v.MSN Laboratories Private Limited
The applicants (Boehringer Ingelheim) filed applications seeking interim directions against the respondents (MSN Laboratories and others) for alleged infringement of their patent covering the compound Linagliptin. The court found that the defendants had not laid any credible challenge to the validity of the patent, thus tilting the balance of convenience in favor of the plaintiffs.
MSN LABORATORIES PRIVATE LIMITED v.THE CONTROLLER OF PATENTS, BOUDHIK SAMPADA BHAVAN, DWARKA, SECTOR-32, PLOT 14 NEW DELHI-400037; BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
The plaintiff (MSN Laboratories) filed a petition seeking the revocation of Indian Patent No. IN 243301. The defendants argued that the petition was time-barred as it was filed more than three years after the patent grant date. The court dismissed the applications, holding that the limitation period for challenging a patent is not necessarily from the date of grant but when the right to sue accrues, and affirming its territorial jurisdiction.
Novartis Ag v.Msn Laboratories Private Limited
Novartis filed a suit seeking permanent injunction against Msn Laboratories Private Limited for alleged infringement of Patent No. 237430 (Inhibitors of Tyrosine Kinases). The dispute centered on whether the Department of Pharmaceuticals' public notice constituted government authorization to manufacture the drug Nilotinib. The court, without considering the merits of infringement or validity, directed that Msn Laboratories must provide four weeks' advance notice before commencing commercial production.
Novartis Ag v.Centurion Remedies Private Limited
Novartis filed a suit seeking permanent injunction and damages against Centurion Remedies Private Limited for infringing Indian Patent No. 229051 concerning pharmaceutical compositions comprising Valsartan and NEP Inhibitors. The court clarified that the Department's Public Notice was merely to collate local manufacturers and did not constitute Government Authorization under Section 100 of the Patents Act, 1970. Consequently, the suit was decreed granting a permanent injunction against Centurion Remedies.
Novartis Ag v.Centurion Remedies Private Limited
Novartis filed a suit seeking permanent injunction and damages against Centurion Remedies Private Limited for alleged infringement of Indian Patent No. 233161. The court examined the defendant's affidavit, which claimed no commercial activity related to the patented drug ELTROMBOPAG OLAMINE/ REVOLADE. Furthermore, the Department of Pharmaceuticals clarified that its public notice was merely for collating local manufacturers and did not constitute government authorization under Section 100 of the Patents Act, 1970.
Pfizer Inc And Ors v.Jodas Expoim Pvt Ltd And Anr
The court framed several issues in this commercial suit concerning alleged patent infringement by the defendants against Pfizer Inc and Ors. The core questions revolve around whether the defendants' activities infringe two specific Indian Patents (No. 218291 and No. 209251) and if the plaintiffs are entitled to permanent injunction or damages.
Novartis Ag v.Msn Laboratories Private Limited
Novartis filed a suit seeking permanent injunction and damages against MSN Laboratories for alleged infringement of Patent No. 283133 concerning Pyrrolopyrimidine compounds. The dispute also involved whether a public notice issued by the Department of Pharmaceuticals constituted government authorization to manufacture the patented drug, Ribociclib.
Merck Sharp And Dohme Corp v.Beaukev Pharma International Pvt. Ltd
Merck Sharp And Dohme Corp filed a suit seeking permanent injunction against Beaukev Pharma International Pvt. Ltd for infringing its registered patent (IN'816) related to Sitagliptin. The dispute was subsequently settled under the Delhi High Court Mediation and Conciliation Centre.
Astrazeneca Ab v.Msn Laboratories Limited
This order was passed in an interim application filed by the Plaintiffs (Astrazeneca Ab). The Defendant (MSN Laboratories Limited), through its counsel, requested a restraint on commercial launch while challenging the patent's validity and rights under Section 107(A) of the Patents Act, 1970.
Novartis Ag v.Msn Laboratories Pvt Ltd
The case involves a dispute over the infringement of a patent related to the drug Pazopanib Hydrochloride. The Plaintiff claims that the Defendant manufactured stock during the patent's lifetime, while the Defendant argues that they launched the product only after the patent expired.
Novartis Ag v.Centurion Remedies Private Limited
Novartis filed a suit seeking permanent injunction against Centurion Remedies Private Limited for alleged infringement of Indian Patent No. 233161, which covers 'ELTROMBOPAG OLAMINE / REVOLADE'. The cause of action arose from an Office Memorandum issued by the Department of Pharmaceuticals indicating that the defendant was included in a list for procuring the patented preparation.
Novartis Ag & Anr. v.Msn Laboratories Private Limited
Novartis filed a suit seeking permanent injunction against Msn Laboratories Private Limited for alleged infringement of Indian Patent No. 283133, which covers PYRROLOPYRIMIDINE (RIBOCICLIB). The cause of action arose from an Office Memorandum indicating the government's intent to procure RIBOCICLIB TAB/CAP, and Novartis argued this posed a threat to its patent rights.
Novartis Ag v.Msn Laboratories Private Limited
Novartis filed a suit seeking permanent injunction against Msn Laboratories for alleged infringement of its patent (No. 237430) covering Inhibitors of Tyrosine Kinases, specifically related to the drug NILOTINIB/TASIGNA. The dispute arose from an Office Memorandum indicating that the Defendant was being considered by the Department of Pharmaceuticals for manufacturing this patented preparation.
Novartis Ag v.Centurion Remedies Private Limited
Novartis Ag filed a suit seeking permanent injunction against Centurion Remedies Private Limited for alleged infringement of Indian Patent No. 229051, which covers pharmaceutical compositions comprising Valsartan and NEP Inhibitors. The cause of action arose from an Office Memorandum issued by the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, listing the defendant for procurement of 'SACUBITRIL + VALSARTAN'.
Astra Zeneca Ab v.Torrent Pharmaceuticals Ltd.
The dispute involved Astra Zeneca alleging infringement of its formulation patents (IN 247984 and IN 272674) by Torrent Pharmaceuticals' product, Ticagrelor. The parties amicably resolved their differences before the Delhi High Court Mediation Centre.
Merck Sharp & Dohme Corp. v.Metrochem Api Pvt. Ltd
The parties amicably resolved their dispute concerning Patent Infringement (CS(COMM) No. 406 of 2019). The Settlement Agreement stipulated that the suit would be decreed in favor of the Plaintiffs, who hold exclusive rights over products containing Sitagliptin.
Bristol-Myers Squibb Holdings Ireland Unlimited Company v.Metrochem Api Private Limited
The Plaintiffs filed a suit seeking permanent injunction against the Defendant for infringing their patent on Lactam-Containing Compounds (Apixaban API). The Defendant submitted an affidavit stating that it had not supplied commercial quantities and agreed to manufacture/sell the drug solely under Section 107A(a) of the Patents Act, leading the Court to pass an interim restraint order.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.